Project Grant R03CA304033
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $167K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $409,158 to the University of Missouri System to evaluate the effectiveness of an oncolytic adenovirus, OADSA-4-1BBL, alone or combined with anti-PD1 blockade in an immunocompetent lung cancer mouse model. The goal is to develop a novel oncolytic adenovirus that preferentially infects and kills lung cancer cells by targeting the transferrin receptor. The central hypothesis is that...
- This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The National Cancer Institute (NCI) awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Icahn School of Medicine at Mount Sinai (ISMMS) to investigate the role of the interferon gamma (IFNγ) signaling pathway in the lung tumor microenvironment and its impact on tumor immunity. The project aims to deconvolute how various components of the IFNγ pathway, including the negative regulator SOCS1, influence immune cell infiltration and response to immune...
- This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer. The $267,527 award will fund research at The University of Texas M.D. Anderson Cancer Center to: 1) Examine the molecular basis for reduced responsiveness to KRAS G12C inhibitors in SMARCA4-mutant lung cancer models, 2) Evaluate the potential of SMARCA2-targeting...
- This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to discover new therapeutic strategies for small cell lung cancer (SCLC). The $191,675 award to The University of Texas Southwestern Medical Center will investigate the role of Jumonji lysine demethylases (Jumonji KDMs) as potential druggable targets in SCLC, including for tumors that have developed resistance to standard chemotherapy. The...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $458,051 to Temple University to conduct research aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key products and services to be delivered under this 4-year award include: Investigating whether low levels of the nuclear structural protein LMNA contribute to the high levels of replication stress observed in SCLC cells, and whether this...
- This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $234,749 to The Ohio State University to conduct a multi-center Phase Ib clinical trial investigating the combination of the Hedgehog inhibitor Vismodegib and the anti-PD-L1 immunotherapy Atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC). The goal is to understand how Hedgehog signaling in tumor-associated macrophages (TAMs) impacts CD8+...